New study data emerges from OrbusNeich's Genous stent study programme
Clinical data published in the International Journal of Cardiology has shown that OrbusNeich's Genous stent is safe and effective in patients who discontinue Dual Antiplatelet Therapy (DAPT) within 15 days of stent placement. Specifically, no differences in rates of stent thrombosis (ST) and other clinical outcomes were observed between patients who discontinued DAPT prior to and after 15 days, according to the results of ARGENTO, a consecutive, prospective study in 384 patients undergoing single or multivessel percutaneous coronary intervention (PCI) with the Genous stent.
In the study, the rate of major adverse cardiac events (MACE) in all patients at follow up (22.8 +/- 13.6 months) was 8.6 per cent. The rate of cardiac death was 3.4 per cent, and myocardial infarction (MI) occurred in the same percentage of patients. In addition, the rate of target vessel revascularisation (TVR) was 4.7 per cent. The overall rate of definite or probable stent thrombosis (ST) was 1.3 per cent. Although not statistically significant, the rates of MACE (4.4 per cent for discontinued DAPT; 9.9 per cent for continued DAPT) and TVR (1.1 per cent for discontinued DAPT; 5.8 per cent for continued DAPT) were lower in the patient group that received a shorter duration of DAPT. Definite or probable ST occurred in 1.1 per cent of patients who discontinued DAPT prior to or at 15 days and in 1.3 per cent of patients who received DAPT beyond 15 days.
The consecutive, prospective study enrolled 384 patients who underwent single or multivessel PCI with Genous stent implantation; a total of 423 lesions were treated. In total, 91 patients discontinued DAPT within 15 days, while 293 received DAPT for more than 15 days. Of the patients treated, 30.5 per cent were diabetics, 37.5 per cent had history of previous MI, and 58.8 per cent had a history of acute coronary syndrome (ACS), including unstable angina, non ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI).